<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
	<channel>
	<link>http://salesandmarketingnetwork.com/hsmn_newsfeed_public.rss</link>
	<title>HSMN NewsFeed</title>
	<description><![CDATA[Healthcare Sales & Marketing Network NewsFeed]]></description>
	<lastBuildDate>Thu, 02 Jul 2009 19:30:04 CST</lastBuildDate>
	<language>en-us</language>
	<image>
	<title><![CDATA[The Healthcare Sales & Marketing Network]]></title>
	<width>150</width>
	<height>67</height>
	<link>http://salesandmarketingnetwork.com/news.php</link>
	<url>http://salesandmarketingnetwork.com/images/hsmn_logo_150.gif</url>
	</image>
	<item>
		 <title><![CDATA[Alcon Discontinues Development of Anecortave Acetate for Intraocular Pressure Reduction]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028456</link>
			<pubDate>Thu, 02 Jul 2009 15:29:26 GMT</pubDate>
			<author><![CDATA[Alcon]]></author>
		 <description><![CDATA[HUENENBERG, Switzerland--(HSMN NewsFeed)--Alcon, Inc. (NYSE:ACL ) announced today that it has discontinued development of anecortave acetate for the reduction of intraocular pressure (IOP) associated with glaucoma. The company recently reviewed interim eff... <br/><font color="red">Biopharmaceuticals, Ophthalmology</font><br/><font color="blue">Alcon, anecortave, intraocular pressure, glaucoma</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Nephros Receives 510k Approval for Dual Stage Ultrafilters]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028455</link>
			<pubDate>Thu, 02 Jul 2009 15:27:31 GMT</pubDate>
			<author><![CDATA[Nephros]]></author>
		 <description><![CDATA[RIVER EDGE, N.J., July 2  (HSMN NewsFeed)  -- Nephros, Inc. (OTC Bulletin Board: NEPH ), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today reported that is h... <br/><font color="red">Devices, FDA</font><br/><font color="blue">Nephros, Dual Stage Ultrafilter, dialysis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028454</link>
			<pubDate>Thu, 02 Jul 2009 15:25:39 GMT</pubDate>
			<author><![CDATA[sanofi-aventis]]></author>
		 <description><![CDATA[Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - - U.S. commercial launch planned for the summer of 2009

PARIS, July 2  (HSMN NewsFeed)  -- Sanofi-aventis (EURONEXT: SAN and... <br/><font color="red">Biopharmaceuticals, Cardiology, FDA</font><br/><font color="blue">sanofi-aventis, Multaq, dronedarone, atrial fibrillation, atrial flutter</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[CombinatoRx and Neuromed Sign Merger Agreement]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028453</link>
			<pubDate>Thu, 02 Jul 2009 15:22:37 GMT</pubDate>
			<author><![CDATA[Neuromed Pharmaceuticals]]></author>
		 <description><![CDATA[Merger to Create a Sustainable Biotechnology Company: Brings Together Significant Product Assets, Unique Discovery Capabilities and Financial Resources

CAMBRIDGE, MA and VANCOUVER, BC, July 2  (HSMN NewsFeed)  - CombinatoRx, Incorporated (NASDAQ: CRXX )... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions, Personnel</font><br/><font color="blue">Neuromed Pharmaceuticals, CombinatoRx</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028452</link>
			<pubDate>Thu, 02 Jul 2009 15:18:27 GMT</pubDate>
			<author><![CDATA[King Pharmaceuticals]]></author>
		 <description><![CDATA[PALATINE, Ill. and BRISTOL, Tenn., July 2  (HSMN NewsFeed)  -- Acura Pharmaceuticals, Inc. (Nasdaq: ACUR ) and King Pharmaceuticals, Inc. (NYSE: KG ) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter reg... <br/><font color="red">Biopharmaceuticals, FDA</font><br/><font color="blue">King Pharmaceuticals, Acura Pharmaceuticals, Acurox, oxycodone</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[RaySearch Wins Breakthrough Order for Proton Treatment Planning System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028451</link>
			<pubDate>Thu, 02 Jul 2009 15:14:46 GMT</pubDate>
			<author><![CDATA[RaySearch Laboratories]]></author>
		 <description><![CDATA[STOCKHOLM--(HSMN NewsFeed)--RaySearch Laboratories AB (STO:RAYB) has entered into a partnership and licensing agreement with Westdeutsches Protonentherapiezentrum Essen gGmbH (WPE). WPE is a proton therapy center under construction at the University Hospit... <br/><font color="red">Devices, Oncology</font><br/><font color="blue">RaySearch Laboratories, proton therapy, proton beam, radiotherapy</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Applied Spine Technologies to Restart U.S. Clinical Trial for Stabilimax NZ(R) Dynamic Spine Stabilization System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028450</link>
			<pubDate>Wed, 01 Jul 2009 20:00:59 GMT</pubDate>
			<author><![CDATA[Applied Spine Technologies]]></author>
		 <description><![CDATA[NEW HAVEN, Conn.--(HSMN NewsFeed)--Applied Spine Technologies (AST), Inc. (www.appliedspine.com), a medical device company focused on motion preservation of the lumbar spine, announces that it has received permission from the U.S. Food and Drug Administrat... <br/><font color="red">Devices, Orthopaedic, Neurosurgery, FDA</font><br/><font color="blue">Applied Spine Technologies, Stabilimax NZ, Spine Stabilization</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028449</link>
			<pubDate>Wed, 01 Jul 2009 19:57:35 GMT</pubDate>
			<author><![CDATA[Shire plc]]></author>
		 <description><![CDATA[VYVANSE is the first stimulant to establish duration of efficacy from two hours up to 14 hours after administration in adults with ADHD

HOLLYWOOD, Fla., July 1  (HSMN NewsFeed)  -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceuti... <br/><font color="red">Biopharmaceuticals</font><br/><font color="blue">Shire plc, VYVANSE, lisdexamfetamine, ADHD</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Eisai and Pfizer Decide not to Appeal NICE Decision and Call for an Expedited Review of Guidance for Alzheimer's Disease]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028448</link>
			<pubDate>Wed, 01 Jul 2009 19:54:40 GMT</pubDate>
			<author><![CDATA[Eisai]]></author>
		 <description><![CDATA[NICE Commit to Reviewing Existing Guidance 'As Soon As Possible'

LONDON, July 1  (HSMN NewsFeed)  -- On June 11, the National Institute for Health and Clinical Excellence (NICE) announced that, following consultation with stakeholders on the economic mo... <br/><font color="red">Biopharmaceuticals, Neurology</font><br/><font color="blue">Eisai, Pfizer, Aricept, donepezil, Alzheimer's disease</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028447</link>
			<pubDate>Wed, 01 Jul 2009 19:50:21 GMT</pubDate>
			<author><![CDATA[Morphotek]]></author>
		 <description><![CDATA[EXTON, Penn., July 1  (HSMN NewsFeed)  -- Morphotek&reg;, Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies fo... <br/><font color="red">Biopharmaceuticals, Oncology</font><br/><font color="blue">Morphotek, Eisai, Synageva BioPharma, monoclonal antibody, farletuzumab</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028445</link>
			<pubDate>Wed, 01 Jul 2009 13:17:41 GMT</pubDate>
			<author><![CDATA[Myriad Pharmaceuticals]]></author>
		 <description><![CDATA[Company Will Advance Three Clinical Development Programs in Oncology and Infectious Disease

Conference Call Scheduled for 10:00 AM EDT On July 1, 2009

SALT LAKE CITY, July 1, 2009 --(HSMN NewsFeed) -- Myriad Pharmaceuticals, Inc. (MPI) today announce... <br/><font color="red">Biopharmaceuticals</font><br/><font color="blue">Myriad Pharmaceuticals, Myriad Genetics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[LabCorp Commences Cash Tender Offer for All Outstanding Shares of Monogram Biosciences, Inc.]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028444</link>
			<pubDate>Wed, 01 Jul 2009 13:11:59 GMT</pubDate>
			<author><![CDATA[Laboratory Corporation of America]]></author>
		 <description><![CDATA[BURLINGTON, N.C.--(HSMN NewsFeed)--Laboratory Corporation of America&reg; Holdings (NYSE: LH ) today announced the commencement of its cash tender offer for all outstanding shares of the common stock of Monogram Biosciences, Inc. (NASDAQ: MGRM ) for $4.55 ... <br/><font color="red">Diagnostics, Mergers & Acquisitions</font><br/><font color="blue">Laboratory Corporation of America, Monogram Biosciences</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[ArthroCare Names Andrew Miclot Senior Vice President, General Manager of ENT Business]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028443</link>
			<pubDate>Wed, 01 Jul 2009 13:07:19 GMT</pubDate>
			<author><![CDATA[ArthroCare]]></author>
		 <description><![CDATA[AUSTIN, Texas--(HSMN NewsFeed)--ArthroCare Corp. (PINK SHEETS: ARTC ) today announced that Andrew Miclot has joined ArthroCare as Senior Vice President, General Manager of ArthroCare’s Ear, Nose and Throat [ENT] Business effective June 29, 2009.

In this... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">ArthroCare</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028442</link>
			<pubDate>Wed, 01 Jul 2009 13:03:41 GMT</pubDate>
			<author><![CDATA[Acorda Therapeutics]]></author>
		 <description><![CDATA[Acorda to Continue to Develop and Commercialize Fampridine-SR in the U.S.

Upfront Payment of $110 Million; Potential Deal Value Over $500 Million

Acorda to Host Conference Call at 8:30 a.m. Eastern Time Today

CAMBRIDGE, Ma. & HAWTHORNE, N.Y.--(HSM... <br/><font color="red">Biopharmaceuticals, Neurology, Licensing</font><br/><font color="blue">Acorda Therapeutics, Biogen Idec, Fampridine-SR, multiple sclerosis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Teva Announces Approval and Launch of Tri-Lo Sprintec Tablets]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028441</link>
			<pubDate>Wed, 01 Jul 2009 12:56:56 GMT</pubDate>
			<author><![CDATA[Teva Pharmaceutical]]></author>
		 <description><![CDATA[JERUSALEM--(HSMN NewsFeed)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) announced today that the U.S. Food and Drug Administration has granted approval for the Company’s Abbreviated New Drug Application (ANDA) to market a generic version of Ortho M... <br/><font color="red">Biopharmaceuticals, Generics, FDA</font><br/><font color="blue">Teva Pharmaceutical, Ortho McNeil Janssen, Ortho Tri-Cyclen Lo, Tri-Lo Sprintec</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[MMDI Announces Agreement with Novation to Supply the Rebound HRD(R)]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028446</link>
			<pubDate>Wed, 01 Jul 2009 04:00:00 GMT</pubDate>
			<author><![CDATA[MMDI]]></author>
		 <description><![CDATA[MINNEAPOLIS, MN, June 30, 2009 – (HSMN NewsFeed) - Minnesota Medical Development, Inc. (MMDI) today announced that it has been awarded an agreement under Novation’s “New Medical Technology” program to supply its Rebound HRD and Rebound HRD V (hernia repair... <br/><font color="red">Devices, Surgery, Group Purchasing</font><br/><font color="blue">MMDI,  Novation, Rebound HRD, hernia repair device</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[FDA Approves Feraheme to Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028440</link>
			<pubDate>Tue, 30 Jun 2009 21:13:07 GMT</pubDate>
			<author><![CDATA[AMAG Pharmaceuticals]]></author>
		 <description><![CDATA[Product launch expected in the second half of July 2009

LEXINGTON, Mass.--(HSMN NewsFeed)--AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG ) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Feraheme™ (ferumoxyt... <br/><font color="red">Biopharmaceuticals, FDA</font><br/><font color="blue">AMAG Pharmaceuticals, Feraheme, ferumoxytol</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Small Bone Innovations, Inc. Raises $144 Million]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028439</link>
			<pubDate>Tue, 30 Jun 2009 21:05:56 GMT</pubDate>
			<author><![CDATA[Small Bone Innovations]]></author>
		 <description><![CDATA[Raises Series D round of $108mm - one of the largest private equity capital financings for an orthopedic company

Raises Series C round of $36mm

Retires $20 million credit facility

NEW YORK--(HSMN NewsFeed)--Small Bone Innovations, Inc. (SBi), an o... <br/><font color="red">Devices, Orthopaedic, Venture Capital</font><br/><font color="blue">Small Bone Innovations</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028438</link>
			<pubDate>Tue, 30 Jun 2009 21:01:27 GMT</pubDate>
			<author><![CDATA[Hospira]]></author>
		 <description><![CDATA[LAKE FOREST, Ill., June 30  (HSMN NewsFeed)  -- Hospira, Inc. (NYSE: HSP ), a global specialty pharmaceutical and medication delivery company, today announced agreements with MedAssets on intravenous (I.V.) solutions and gravity I.V. equipment, and a renew... <br/><font color="red">Biopharmaceuticals, Group Purchasing</font><br/><font color="blue">Hospira, MedAssets</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Study Finds Edwards Lifesciences' Port Access System Facilitates Improved Outcomes Compared to Sternotomy]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028437</link>
			<pubDate>Tue, 30 Jun 2009 13:18:09 GMT</pubDate>
			<author><![CDATA[Edwards Lifesciences]]></author>
		 <description><![CDATA[Edwards Lifesciences Corporation -(HSMN NewsFeed)- (NYSE:EW ), the global leader in the science of heart valves, announced that new research demonstrates that using its minimally invasive PORT ACCESS System in mitral valve surgery significantly decreases t... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">Edwards Lifesciences, PORT ACCESS System, mitral valve repair</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028436</link>
			<pubDate>Tue, 30 Jun 2009 13:11:19 GMT</pubDate>
			<author><![CDATA[Catalyst Biosciences]]></author>
		 <description><![CDATA[Multi-Product Collaboration Valued Potentially at More Than $500 Million

COLLEGEVILLE, Pa., and SOUTH SAN FRANCISCO, Calif., June 30  (HSMN NewsFeed)  -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ) and Catalyst Biosciences, Inc. today announ... <br/><font color="red">Biopharmaceuticals</font><br/><font color="blue">Catalyst Biosciences, Wyeth Pharmaceuticals, Factor VIIa, hemophilia</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Gore Receives FDA Approval for Modification of GORE VIABAHN® Endoprosthesis]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028435</link>
			<pubDate>Tue, 30 Jun 2009 13:07:52 GMT</pubDate>
			<author><![CDATA[W. L. Gore]]></author>
		 <description><![CDATA[Manufacturing modification of the only stent-graft approved for treatment of both iliac and superficial femoral arteries

FLAGSTAFF, Ariz.--(HSMN NewsFeed)--W. L. Gore & Associates (Gore) today announced that it has received approval from the US Food and... <br/><font color="red">Devices, Interventional, FDA</font><br/><font color="blue">W. L. Gore, GORE VIABAHN, Endoprosthesis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Hyperion Therapeutics Raises $60 Million Series C]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028434</link>
			<pubDate>Tue, 30 Jun 2009 13:04:35 GMT</pubDate>
			<author><![CDATA[Hyperion Therapeutics]]></author>
		 <description><![CDATA[SOUTH SAN FRANCISCO, Calif., June 30  (HSMN NewsFeed)  -- Hyperion Therapeutics, a privately held specialty pharmaceutical company focused on the development of therapies that address critical unmet needs in the areas of gastroenterology and hepatology, to... <br/><font color="red">Biopharmaceuticals, Venture Capital</font><br/><font color="blue">Hyperion Therapeutics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028433</link>
			<pubDate>Tue, 30 Jun 2009 13:01:21 GMT</pubDate>
			<author><![CDATA[Cell Genesys]]></author>
		 <description><![CDATA[Merged Company Will Focus on LibiGel&reg; in Phase III Clinical Studies for Female Sexual Dysfunction and Seek Future Opportunities for GVAX Immunotherapies

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--BioSante Pharmaceuticals, Inc... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions</font><br/><font color="blue">Cell Genesys, BioSante Pharmaceuticals, LibiGel</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Tryton Announces First Patient Enrollment in E-Tryton 150 Registry]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028432</link>
			<pubDate>Tue, 30 Jun 2009 12:56:01 GMT</pubDate>
			<author><![CDATA[Tryton Medical]]></author>
		 <description><![CDATA[Study Will Assess Tryton Side-Branch Stent in Real-World Settings

RESEARCH TRIANGLE PARK, N.C.--(HSMN NewsFeed)--Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced enrollment of the ... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Tryton Medical, E-Tryton 150, Side Branch Stent, bifurcation</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028431</link>
			<pubDate>Mon, 29 Jun 2009 15:39:21 GMT</pubDate>
			<author><![CDATA[DOR BioPharma]]></author>
		 <description><![CDATA[PRINCETON, N.J., June 29  (HSMN NewsFeed)  -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB ), a late-stage biopharmaceutical company, announced today that investigators at the Fred Hutchinson Cancer Research Center, Seattle, Washingto... <br/><font color="red">Biopharmaceuticals</font><br/><font color="blue">DOR BioPharma, orBec , beclomethasone, GI GVHD</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028430</link>
			<pubDate>Mon, 29 Jun 2009 14:22:57 GMT</pubDate>
			<author><![CDATA[Horizon Therapeutics]]></author>
		 <description><![CDATA[Dr. Sherman also elected President of the Drug Information Association (DIA)

NORTHBROOK, Ill., June 29  (HSMN NewsFeed)  -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced the appointment of Jeffrey W. Sherman, M.... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Horizon Therapeutics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin(R) (Human Growth Hormone)]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028429</link>
			<pubDate>Mon, 29 Jun 2009 14:20:24 GMT</pubDate>
			<author><![CDATA[Teva Pharmaceutical]]></author>
		 <description><![CDATA[New patient-friendly option to be made available for Tev-Tropin

JERUSALEM & EWING, N.J.--(HSMN NewsFeed)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) and its partner, Antares Pharma, Inc. (NYSE Amex: AIS) today announced the approval of a Supple... <br/><font color="red">Biopharmaceuticals, Drug Delivery, FDA</font><br/><font color="blue">Teva Pharmaceutical, Antares Pharma, Tev-Tropin</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Watson Pharmaceuticals Appoints Christopher W. Bodine to Board of Directors]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028428</link>
			<pubDate>Mon, 29 Jun 2009 14:13:26 GMT</pubDate>
			<author><![CDATA[Watson Pharmaceuticals]]></author>
		 <description><![CDATA[Former President, Health Care Services for CVS Caremark Corporation Brings Added Global Supply Chain Experience and Expertise to the Board

MORRISTOWN, N.J., June 29  (HSMN NewsFeed)  -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leader in generic and ... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Watson Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Wake Pharm US Announces Appointment of Jeffrey A. Niezgoda, M.D. to the Board of Medical Advisors]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028427</link>
			<pubDate>Mon, 29 Jun 2009 13:38:22 GMT</pubDate>
			<author><![CDATA[Wake Pharm US]]></author>
		 <description><![CDATA[ELK GROVE VILLAGE, Ill., June 29  (HSMN NewsFeed)  -- Wake Pharm US announced today the appointment of Jeffrey A. Niezgoda, MD, FACHM, FACEP, FAPWCA as Director of the Company's Medical Advisory Board.

Dr. Jeffrey Niezgoda is a leading wound management ... <br/><font color="red">Biopharmaceuticals, Wound Care, Personnel</font><br/><font color="blue">Wake Pharm US</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028426</link>
			<pubDate>Fri, 26 Jun 2009 16:37:16 GMT</pubDate>
			<author><![CDATA[ISTA Pharmaceuticals]]></author>
		 <description><![CDATA[IRVINE, Calif., June 26  (HSMN NewsFeed)  -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ) today announced the Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended the approval of Bepreve(TM... <br/><font color="red">Biopharmaceuticals, Ophthalmology</font><br/><font color="blue">ISTA Pharmaceuticals, Bepreve, bepotastine</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028425</link>
			<pubDate>Fri, 26 Jun 2009 13:15:32 GMT</pubDate>
			<author><![CDATA[Schering-Plough]]></author>
		 <description><![CDATA[Positive Opinion Recommends Approval of New Anti-TNF Therapy in Three Rheumatic Diseases with Novel SmartJect(TM) Autoinjector

HORSHAM, Pa. and KENILWORTH, N.J., June 26  (HSMN NewsFeed)  -- Centocor Ortho Biotech Inc. and Schering-Plough Corporation (N... <br/><font color="red">Biopharmaceuticals, Regulatory</font><br/><font color="blue">Schering-Plough, Centocor Ortho Biotech, SIMPONI, golimumab</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[AZZALURE(R) Approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2028424</link>
			<pubDate>Fri, 26 Jun 2009 13:09:02 GMT</pubDate>
			<author><![CDATA[Ipsen]]></author>
		 <description><![CDATA[This market authorisation is part of a process including 15 countries in Europe 
Azzalure(R) will be commercialised in Germany by Galderma

PARIS & LAUSANNE, Switzerland--(HSMN NewsFeed)--Galderma, the leading pharmaceutical company in dermatology, and ... <br/><font color="red">Biopharmaceuticals, Dermatology, Regulatory</font><br/><font color="blue">Ipsen, Galderma, Azzalure, botulinum toxin Type A, glabellar lines</font>]]>
			</description>
	</item>
	</channel>
</rss>